These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 2539786)

  • 21. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors.
    Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3659-63. PubMed ID: 15203138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural inhibitors of DNA topoisomerase I with cytotoxicities.
    Han HJ; Tan NH; Zeng GZ; Fan JT; Huang HQ; Ji CJ; Jia RR; Zhao QS; Zhang YJ; Hao XJ; Wang LQ
    Chem Biodivers; 2008 Jul; 5(7):1364-8. PubMed ID: 18649302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [NB 506].
    Lansiaux A; Bailly C
    Bull Cancer; 1999 Mar; 86(3):255-8. PubMed ID: 10210758
    [No Abstract]   [Full Text] [Related]  

  • 24. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.
    Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF
    Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.
    Barret JM; Kruczynski A; Etiévant C; Hill BT
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):479-86. PubMed ID: 12107553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time-temperature parameters and scheduling protocols.
    Ng CE; Raaphorst GP
    Int J Hyperthermia; 1996; 12(5):701. PubMed ID: 8886895
    [No Abstract]   [Full Text] [Related]  

  • 27. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
    Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
    J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Strategies for the overcoming of drug resistance].
    Saijo N
    Gan To Kagaku Ryoho; 1995 Feb; 22(3):371-81. PubMed ID: 7880108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA topoisomerases as anticancer drug targets.
    Schneider E; Hsiang YH; Liu LF
    Adv Pharmacol; 1990; 21():149-83. PubMed ID: 2176094
    [No Abstract]   [Full Text] [Related]  

  • 30. [Resistance of cancer cells to antineoplastic agents. Can the efficiency of chemotherapy be predicted?].
    Bénard J
    Rev Prat; 1992 Feb; 42(3):318-9. PubMed ID: 1579821
    [No Abstract]   [Full Text] [Related]  

  • 31. Involvement of DNA topoisomerases and DNA topoisomerase inhibitors in the induction of leukemia cell differentiation.
    Larsen AK
    Ann Oncol; 1994 Oct; 5(8):679-88. PubMed ID: 7826899
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecular and clinical advances in anticancer drug resistance.
    Cancer Treat Res; 1991; 57():1-308. PubMed ID: 1686711
    [No Abstract]   [Full Text] [Related]  

  • 33. Anthracycline and anthraquinone anticancer agents: current status and recent developments.
    Lown JW
    Pharmacol Ther; 1993 Nov; 60(2):185-214. PubMed ID: 8022857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thermostability of cytostatic drugs in vitro and thermosensitivity of cultured human lymphoblasts against cytostatic drugs.
    Voth B; Sauer H; Wilmanns W
    Recent Results Cancer Res; 1988; 107():170-6. PubMed ID: 3375548
    [No Abstract]   [Full Text] [Related]  

  • 35. The action of anticancer chemotherapeutics on some crystalline enzymes.
    KELETI T
    Neoplasma; 1961; 8():487-94. PubMed ID: 14454913
    [No Abstract]   [Full Text] [Related]  

  • 36. [DNA topoisomerases and resistance to anticancer agents].
    Andoh T; Okada K
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):569-75. PubMed ID: 2539786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].
    Ishida R; Andoh T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):952-61. PubMed ID: 8002633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance.
    Liu LF; D'Arpa P
    Important Adv Oncol; 1992; ():79-89. PubMed ID: 1316311
    [No Abstract]   [Full Text] [Related]  

  • 39. DNA topoisomerases and topoisomerase inhibitors.
    Giaccone G
    Pathol Biol (Paris); 1994 Apr; 42(4):346-52. PubMed ID: 7808789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
    Pourquier P; Pommier Y
    Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.